


Neurophet SCALE PET supports clinical decision

Concordance of interpretation

Amyloid PET ¹⁾


Amyloidosis Yes No



	AUC	ACC	SEN	SPEC
Neurophet SCALE PET	0.9593	0.9833	0.9412	0.9774

Reference region: Pons (Cut-off: 0.61)

Tau PET ²⁾



	ACC
Neurophet SCALE PET	0.822

Reference region: Cerebellar cortex (Cut-off: 1.65) / A Priori ROI

Inter-rater Kappa on Amyloid PET positivity ³⁾

*Validated in 3 university hospitals

*Compared with the standard reference determined with the agreement between two raters

*Rater 1: Experienced Nuclear Medicine (>10 years) / Rater 2: General Nuclear Medicine(<3 years)

Site 1

Florbetaben
(N=119)


Rater 1 (Experienced NM)
Rater 2 (General NM)



Site 2

Flutemetamol
(N=128)


Rater 1 (Experienced NM)
Rater 2 (General NM)



Site 3

Flutemetamol
(N=100)

Rater 1 (Experienced NM)
Rater 2 (General NM)



Ref. 1) Jiyeon Lee et al. Diagnostic 12(3), (2022) 623

2-3) Data on file, Neurophet Inc, CLIN-09-0001, CLIN-18-0001, GNT-04-0001, GNT-07-0001

4) Data on file, Neurophet Inc, 10620_DHF_UMKO